Our findings revealed that reduced stemness and proliferative capacity in G2/M-accumulated cells mediated by ABCB1 inhibition decreased the level of drug sensitivity in p53null ovarian cancer cells, but not in p53-expressing cells, suggesting that the strategy to overcome acquired resistance to carboplatin might differ depending on the mutation status of the TP53 gene. This evidence concerns the gene TP53 and ovarian carcinoma.